GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ANS-6637 overview

ANS-6637 (GS-6637) is under development for the treatment of cocaine, opiate craving and binge eating disorder. It is formulated as a tablet and administered through the oral route. The drug candidate acts by targetting acetaldehyde dehydrogenase-2 (ALDH2) inhibitor. It was also under development for the treatment of alcohol addiction, smoking cessation.

Amygdala Neurosciences overview

Amygdala Neurosciences is a biopharmaceutical company. The company develops novel therapeutics for the treatment of opioid, nicotine, alcohol and cocaine use disorders. Amygdala Neurosciences is headquartered in Palo Alto, California, the US.

For a complete picture of ANS-6637’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.